Morgan Stanley Maintains Overweight on Inari Medical, Lowers Price Target to $83

Benzinga · 01/06/2023 14:40
Morgan Stanley analyst Cecilia Furlong maintains Inari Medical (NASDAQ:NARI) with a Overweight and lowers the price target from $95 to $83.